DDMAC Goes After Clinical Trial Evidence Again
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's ad division finds fault with the quality of the clinical trial evidence used to support claims in promotional material for Genentech's Rituxan.
You may also be interested in...
FDA Rains Down Criticism On Noven's Umbrella Claim
DDMAC frowns on Noven Pharmaceuticals' attempt to bring together major depressive disorder and generalized anxiety disorder and claim that Pexeva (paroxetine mesylate) treats the combination.
FDA Rains Down Criticism On Noven's Umbrella Claim
DDMAC frowns on Noven Pharmaceuticals' attempt to bring together major depressive disorder and generalized anxiety disorder and claim that Pexeva (paroxetine mesylate) treats the combination.
Convenience Claims Can Put Companies On Slippery Promotional Ground
FDA cites an ad for Sanofi-Aventis' prostate cancer therapy Eligard for implying better patient quality of life and more physician efficiency because of less-frequent injections.